



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-GPRC5D & CD3 Reference Antibody (Talquetamab)	Lot.No.:	P247885- P247881
Target:	CD3, GPRC5D / GPC5D	Catalog:	CHBA026
Target Accession:	Q9NZD1 & P07766	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	144.98 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

MASS




The detected molecular weight of Anti-GPRC5D & CD3 Reference Antibody (Talquetamab) is 144.32 kDa.

Purity: SDS-PAGE




Anti-GPRC5D & CD3 Reference Antibody (Talquetamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-GPRC5D & CD3 Reference Antibody (Talquetamab) is more than 97.10%, determined by SEC-HPLC.


Bioactivity: ELISA



Talquetamab bound to GPRC5D protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Talquetamab bound to hu-GPRC5D-VLP, and the EC₅₀ was 0.978 nM.


The products are for research use only. Not for use in diagnostic procedures.

Bioactivity: FACS




Talquetamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Talquetamab bound to huCD3e-jurkat cells, and the EC50 was 6.175 nM.

Bioactivity: FACS



Talquetamab bound to huGPC5D-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig 3, Talquetamab bound to huGPC5D-HEK293 cells, and the EC50 was 2.067 nM.

Function: Luciferase



Plated and cultivated Talquetamab at 4°C overnight, then with the addition of NF-AT-Jurkat cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Talquetamab was able to activate the NF-AT signaling pathway, and the EC50 was 7.499 nM.

The products are for research use only. Not for use in diagnostic procedures.